Bristol-Myers Squibb has sprinted to an early lead in the race to sell a class of cancer treatment by bucking the trend toward precision medicine and sticking to the mass-marketing approach in selling its drug, Opdivo.
from WSJ.com: US Business http://ift.tt/1QWEZOx
via IFTTT
No comments:
Post a Comment